Navigation Links
TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
Date:8/30/2007

LA JOLLA, Calif., Aug. 30 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that Dr. Neil Kurtz, President and Chief Executive Officer of TorreyPines, will present at the NewsMakers in the Biotech Industry Conference in New York on Thursday, September 6th at 3:00 p.m., Eastern Time.

A webcast of Dr. Kurtz's presentation will be available live. You can access the webcast at: http://www.torreypinestherapeutics.com. An archived version of the remarks will also be available through the Company's web site for a limited time following the conference.

About TorreyPines Therapeutics

TorreyPines Therapeutics, Inc. is a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel small molecules to treat diseases and disorders of the central nervous system (CNS). Led by an accomplished management team, TorreyPines is leveraging novel drug targets and technologies to potentially deliver new CNS therapies for chronic pain, including migraine and neuropathic pain; and cognitive disorders, including cognitive impairment associated with schizophrenia and Alzheimer's disease. Further information is available at http://www.torreypinestherapeutics.com.


'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
3. Wisconsin firms to present at Cleantech venture capital event
4. New Sonic Foundry search engine finds words, phrases in video presentations
5. Lone Wisconsin firm to present at InvestMidwest
6. Sonic Foundry creates search engine for 7,000 expert video presentations
7. InvestMidWest calls for business presentations
8. Wicab to present BrainPort at Boston conference
9. Three more Wisconsin firms to present at venture forum
10. Six Wisconsin firms to present at BIO Mid-America VentureForum
11. New Health and Human Services representative for Midwest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... With the accelerated aging of the ... as well as the improved medical care facilities ... industry has been developing quickly, especially in vitro ... in vitro diagnostics market size reached RMB22.98 billion, ... diagnostic reagents. , Read complete report with ...
(Date:7/30/2014)... 30, 2014  Orexigen Therapeutics, Inc. (Nasdaq: ... 180 List of Outstanding Issues (LOI) from the European ... (CHMP) for the NB32 Marketing Authorization Application (MAA). NB32 ... investigational drug candidate being evaluated for weight loss. ... time point were adequately addressed by the Company based ...
(Date:7/30/2014)... July 30, 2014  RXi Pharmaceuticals Corporation ... company focused on discovering, developing and commercializing ... using RNA-targeted technologies, today announced that their ... for the reduction of recurrence of hypertrophic ... been initiated. Logo - ...
(Date:7/30/2014)... Immunology Summit-2014 will be ... scientists in the field, which includes prominent personalities ... Western Reserve University School of Medicine, USA, who ... “The effects of recombinant human IL-6 and recombinant ... Biragyn, a Senior investigator at National Institute on ...
Breaking Biology Technology:China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5Unveiling Breakthroughs in Clinical & Cellular Immunology 2Unveiling Breakthroughs in Clinical & Cellular Immunology 3
... GREENWOOD VILLAGE, Colo., Dec. 22, 2011 Ampio Pharmaceuticals, ... or the "Company"), a company that discovers and develops ... entities ("NMEs"), today announced notification of the granting of ... METHOD OF USING DIKETOPIPERAZINES AND COMPOSITION CONTAINING THEM". ...
... Mich., Dec. 22, 2011  Neogen Corporation (NASDAQ: NEOG ... of FY 2012, which ended Nov. 30, increased 2.2% from ... the quarter was $5,237,000, or $0.22 per share, compared to ... $0.26 per share. Year-to-date revenues for the first ...
... 2011 Epitomics, Inc., a California based biotech ... a Star Program in collaboration with the University ... application of a new, advanced antibody assay technique, ... measurements of antibody-antigen interactions. Over the course of ...
Cached Biology Technology:Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™ 2Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™ 3Neogen Reports Second Quarter Results 2Neogen Reports Second Quarter Results 3Neogen Reports Second Quarter Results 4Neogen Reports Second Quarter Results 5Neogen Reports Second Quarter Results 6Epitomics, Inc. and University of California, Davis, Complete Star Program for High-Throughput Measurement of Antibody-Antigen Interactions 2
(Date:7/30/2014)... pieces is still in its infant stage. But it ... major significance. "Amazingly often, we are findingin addition to ... we found in Baltic amber," explained Bonn paleontologist Professor ... from the Baltic Sea region, which is almost 10,000 ... the coastal regions of Mecklenburg, Poland and Belarus. The ...
(Date:7/30/2014)... unveiled the first high-resolution map of the carbon ... of Per. The new and improved methodology used ... for future market-based carbon economies. The new ... diversity and it provides the critical input to ... land use, and enforcement purposes. The technique includes ...
(Date:7/29/2014)... Bristol,s Nutrition and Behaviour Unit (NBU) has looked into ... meals. , The research, to be presented at the ... 2014) in Seattle, USA this week [29 July to ... was led by Professor Jeff Brunstrom, and is based ... of a Biotechnology and Biological Sciences Research Council (BBSRC) ...
Breaking Biology News(10 mins):Chinese mosquitos on the Baltic Sea 2Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3
... Los Angeles, London, New Delhi, Singapore and Washington DC (July ... be advertised directly to the patient, and the results of ... the future adoption of pharmacogenetic/genomic testing, according to a position ... be published in the August 2009 issue of the ...
... many couples conceive healthy children and is generally considered ... PGD in mice suggests that this procedure may increase ... PGD is used alongside assisted reproduction technologies ... disease (e.g. Ashkenazi Jews who have a high incidence ...
... the July issue of Biomaterials , published by ... report on the first lab-grown motor nerves that are ... human body. The model system will drastically improve ... diabetic neuropathy and later, possibly multiple sclerosis (MS). In ...
Cached Biology News:Genetic tests advertised directly to the consumer 2Preimplantation genetic diagnosis may pose neurological risks 2Researchers design first model motor nerve system that's insulated and organized like the human body 2
Applications: Western blotting ...
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
Required to perform reference file generation, flatfield calibration and performance verification processes on the GSD-501...
... Amplification Kit, 100 reactions. Prepare circular ... 4-6 h.Generate microgram quantities of template ... material.Use amplified DNA directly for cycle ... or M13 liquid cultures, colonies, plaques, ...
Biology Products: